Prostate imaging reporting and data system (PI-RADS) for assessment of pathologic outcomes and clinical characteristics in patients with prostate cancer confirmed by biopsy

doi:10.3877/cma.j.issn.2095-655X.2017.04.012

Abstract

Abstract:

Objective

To explore the prostate imaging reporting and data system (PI-RADS) for assessment of pathologic outcomes and clinical characteristics after radical prostatectomy (RP) who confirmed by biopsy.

Methods

The patients who underwent multiple parameter MRI (mpMRI) and were diagnosed by prostate cancer (PCa) from January 2013 to June 2017 were reviewed retrospectively.Of which, 81 patients were screened after RP in patients with GS 3+ 4=7 tumor at biopsy.Two radiologists assessed mpMRI with double blind method and assigned PI-RADS categories (categories 1~5), which compared to the GS, and the presence of extracapsular extension (ECE) after RP.

Results

53.1% of patients (43/81) had ECE, and 2.5% (2/81) had their tumors downgraded to GS 3+ 3=6, whereas 21.0% (17/81) had GS 4+ 3=7 PCa after RP.PI-RADS showed moderate accuracy for the diagnosis of GS 4+ 3≥7 tumors (AUC, 0.65; 95% CI, 0.54~0.77) and moderate accuracy for the ECE (AUC, 0.72; 95%CI, 0.62~0.87). The sensitivity of PI-RADS score of 3 or higher was 100% for diagnosis of GS 4+ 3=7 PCa.PI-RADS category of 4 or higher for diagnosis of PCa were 94.1% and 23.4%, respectively.Interobserver agreement was moderate (κ=0.43).

Conclusion

For GS 3+ 4=7 cancers detected at biopsy, higher PI-RADS categories are associated with upgrading to GS 4+ 3=7 and the presence of ECE after RP.

Key words: Prostate imaging reporting and data system, Prostatic neoplasms, Extracapsular extension

Litao Zhang, Xiujuan Li, Xiaolin Zhu, Zhenbo Ma, Deting Ma, Yuanzhong Xie. Prostate imaging reporting and data system (PI-RADS) for assessment of pathologic outcomes and clinical characteristics in patients with prostate cancer confirmed by biopsy[J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(04): 267-271.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2017.04.012

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2017/V05/I04/267

Figures/Tables 1

References 34

[1]	韩苏军,张思维,陈万青, 等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志, 2013, 18(4): 330-334.
[2]	Mohler J,Bahnson RR,Boston B, et al.NCCN clinical practice guidelines in oncology：prostate cancer[J]. J Natl Compr Canc Netw, 2010, 8(2): 162-200.
[3]	Thomsen FB,Brasso K,Klotz LH, et al.Active surveillance for clinically localized prostate cancer-a systematic review[J]. J Surg Oncol, 2014, 109(8): 830-835.
[4]	Morash C,Tey R,Agbassi C, et al.Active surveillance for the management of localized prostate cancer：guideline recommendations[J]. Can Urol Assoc J, 2015, 9(5-6): 171-178.
[5]	Epstein JI,Zelefsky MJ,Sjoberg DD, et al.A contemporary prostate cancer grading system：a validated alternative to the gleason score[J]. Eur Urol, 2016, 69(3): 428-435.
[6]	de Rooij M,Hamoen EH,Fütterer JJ, et al.Accuracy of multiparametric MRI for prostate cancer detection：a meta-analysis[J]. AJR Am J Roentgenol, 2014, 202(2): 343-351.
[7]	Hegde JV,Mulkern RV,Panych LP, et al.Multiparametric MRI of prostate cancer：an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer[J]. J Magn Reson Imaging, 2013, 37(5): 1035-1054.
[8]	张立涛,李秀娟,韩耀启, 等. 磁共振T2加权成像联合弥散加权成像对前列腺癌包膜外扩散的预测价值[J/CD]. 中华诊断学电子杂志, 2016, 4(4): 226-230.
[9]	Weinreb JC,Barentsz JO,Choyke PL, et al.PI-RADS prostate imaging-reporting and data system：2015, Version 2[J]. Eur Urol, 2016, 69(1): 16-40.
[10]	Barentsz JO,Weinreb JC,Verma S, et al.Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use[J]. Eur Urol, 2016, 69(1): 41-49.
[11]	Woo S,Kim SY,Lee J, et al.PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy：a preliminary study in patients with biopsy-proven Gleason Score 7 (3＋4) prostate cancer[J]. Eur Radiol, 2016, 26(10): 3580-3587.
[12]	Park SY,Oh YT,Jung DC, et al.Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers：initial results[J]. Eur Radiol, 2016, 26(8): 2502-2509.
[13]	Muller BG,Shih JH,Sankineni S, et al.Prostate cancer：interobserver agreement and accuracy with the revised prostate imaging reporting and data system at multiparametric MR imaging[J]. Radiology, 2015, 277(3): 741-750.
[14]	Epstein JI,Feng Z,Trock BJ, et al.Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy：incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades[J]. Eur Urol, 2012, 61(5): 1019-1024.
[15]	Freedland SJ,Kane CJ,Amling CL, et al.Upgrading and downgrading of prostate needle biopsy specimens：risk factors and clinical implications[J]. Urology, 2007, 69(3): 495-499.
[16]	Gondo T,Hricak H,Sala E, et al.Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 ＋ 4 prostate cancer[J]. Eur Radiol, 2014, 24(12): 3161-3170.
[17]	Woo S,Kim SY,Lee J, et al.PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy：a preliminary study in patients with biopsy-proven Gleason Score 7 (3＋4) prostate cancer[J]. Eur Radiol, 2016, 26(10): 3580-3587.
[18]	Rosenkrantz AB,Kim S,Lim RP, et al.Prostate cancer localization using multiparametric MR imaging：comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales[J]. Radiology, 2013, 269(2): 482-492.
[19]	Turkbey B,Shah VP,Pang Y, et al.Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images？[J]. Radiology, 2011, 258(2): 488-495.
[20]	Kim JY,Kim SH,Kim YH, et al.Low-risk prostate cancer：the accuracy of multiparametric MR imaging for detection[J]. Radiology, 2014, 271(2): 435-444.
[21]	Yerram NK,Volkin D,Turkbey B, et al.Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer[J]. BJU Int, 2012, 110(11 b): E783-E788.
[22]	Turkbey B,Mani H,Aras O, et al.Prostate cancer：can multiparametric MR imaging help identify patients who are candidates for active surveillance？[J]. Radiology, 2013, 268(1): 144-152.
[23]	Lim C,Flood TA,Hakim SW, et al.Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma[J]. J Magn Reson Imaging, 2016, 43(3): 726-736.
[24]	Baco E,Rud E,Eri LM, et al.A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy[J]. Eur Urol, 2016, 69(1): 149-156.
[25]	Rosenkrantz AB,Shanbhogue AK,Wang A, et al.Length of capsular contact for diagnosing extraprostatic extension on prostate MRI：Assessment at an optimal threshold[J]. J Magn Reson Imaging, 2016, 43(4): 990-997.
[26]	Lim CS,Mclnnes MDF,Flood TA, et al.Prostate imaging reporting and data system, version 2, assessment categories and pathologic outcomes in patients with gleason score 3＋4＝7 prostate cancer diagnosed at biopsy[J]. AJR Am J Roentgenol, 2017, 208(5): 1037-1044.
[27]	Chong Y,Kim CK,Park SY, et al.Value of diffusion-weighted imaging at 3 T for prediction of extracapsular extension in patients with prostate cancer：a preliminary study[J]. AJR Am J Roentgenol, 2014, 202(4): 772-777.
[28]	Rozenberg R,Thornhill RE,Flood TA, et al.Whole-tumor quantitative apparent diffusion coefficient histogram and texture analysis to predict gleason score upgrading in intermediate-risk 3＋4＝7 prostate cancer[J]. AJR Am J Roentgenol, 2016, 206(4): 775-782.
[29]	de Rooij M,Hamoen EH,Witjes JA, et al.Accuracy of magnetic resonance imaging for local staging of prostate cancer：a diagnostic meta-analysis[J]. Eur Urol, 2016, 70(2): 233-245.
[30]	Ruprecht O,Weisser P,Bodelle B, et al.MRI of the prostate：interobserver agreement compared with histopathologic outcome after radical prostatectomy[J]. Eur J Radiol, 2012, 81(3): 456-460.
[31]	Hoeks CM,Barentsz JO,Hambrock T, et al.Prostate cancer：multiparametric MR imaging for detection, localization, and staging[J]. Radiology, 2011, 261(1): 46-66.
[32]	Engelbrecht MR,Jager GJ,Laheij RJ, et al.Local staging of prostate cancer using magnetic resonance imaging：a meta-analysis[J]. Eur Radiol, 2002, 12(9): 2294-2302.
[33]	Kayat Bittencourt L,Litjens G,Hulsbergen-van de Kaa CA, et al.Prostate Cancer：The european society of urogenital radiology prostate imaging reporting and data system criteria for predicting extraprostatic extension by using 3-T multiparametric MR imaging[J]. Radiology, 2015, 276(2): 479-489.
[34]	Schieda N,Quon JS,Lim C, et al.Evaluation of the european society of urogenital radiology (ESUR) PI-RADS scoring system for assessment of extra-prostatic extension in prostatic carcinoma[J]. Eur J Radiol, 2015, 84(10): 1843-1848.

PI-RADS评分	GS 4＋3≥7		包膜外扩散
PI-RADS评分	敏感度	特异度	敏感度	特异度
≥1分	100.00	0.00	100.00	0.00
≥2分	100.00	6.30	97.70	7.90
≥3分	100.00	9.40	97.70	13.20
≥4分	94.10	23.40	88.40	28.90
≥5分	70.60	56.30	69.80	73.70
AUC(95% CI)	0.65 (0.54～0.77)		0.72 (0.62～0.87)

PI-RADS评分	GS 4＋3≥7		包膜外扩散
PI-RADS评分	敏感度	特异度	敏感度	特异度
≥1分	100.00	0.00	100.00	0.00
≥2分	100.00	6.30	97.70	7.90
≥3分	100.00	9.40	97.70	13.20
≥4分	94.10	23.40	88.40	28.90
≥5分	70.60	56.30	69.80	73.70
AUC(95% CI)	0.65 (0.54～0.77)		0.72 (0.62～0.87)

Please choose a citation manager

Content to export